TY - JOUR
T1 - Treatment adherence, healthcare resource utilization, and costs in patients with lung neuroendocrine tumors (lung NETs) in the USA
AU - Broder, Michael S.
AU - Cai, Beilei
AU - Chang, Eunice
AU - Yan, Tingjian
AU - Benson, Al B.
N1 - Funding Information:
Funding for this study was provided by Novartis Pharmaceuticals Corporation.
Funding Information:
B.C. is an employee and shareholder of Novartis Pharmaceuticals Corporation. A.B.B. is an employee of Northwestern University and was paid by Novartis to consult as a subject matter expert. A.B.B. declares grant funding from Acerta, Celgene, Advanced Accelerator App., Novartis, Infinity Pharmaceuticals, Merck Sharp & Dohme, Taiho Pharmaceuticals, Bristol-Myers Squibb, Medimmune/AstraZeneca, Xencor; consultancy for Genentech/Roche, Bristol-Myers Squibb, Celgene, Taiho, Boehringer Ingelheim, EMD Serono, Integragen, Guardant, Opsona Therapeutics, Lexicon, Novartis, Boston Biomedical, Helsinn, Guerbet, Eli Lilly, TRM Oncology, Immunogen, Pfizer, Exelixis, Oncosil Medical, Purdue Pharma, Halozyme Therapeutics, AstraZeneca, Rafael Pharmaceuticals. M.S.B., E.C. and T.Y. are employees of Partnership for Health Analytic Research, LLC (PHAR, LLC), a health services research company paid by Novartis to conduct this research. CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/12/2
Y1 - 2018/12/2
N2 - Objective: To assess first-line treatment adherence, healthcare resource utilization, and costs in lung NET patients initiating pharmacologic treatments. Methods: In two US claims databases, patients aged ≥18 years with ≥1 inpatient or ≥2 outpatient lung NET claims within 12 months were identified. The first claim for pharmacologic treatments (e.g. somatostatin analogs [SSAs], cytotoxic chemotherapy [CC], targeted therapy [TT]) following diagnosis, between July 1, 2009–December 31, 2014, was defined as the index date. A 6-month pre-index period without any NET treatment, and ≥1-year post-index enrollment were required. Proportion of days covered (PDC) was calculated during follow-up. Descriptive statistics, including means, standard deviations, and frequencies/percentages for continuous and categorical data, respectively, were reported. Results: Of 354 patients with 1-year of follow-up, 252 initiated CC, 89 SSA, 3 TT, and 10 various combinations. Due to sample sizes, the remaining results focus only on CC and SSAs. Mean PDC (SD) was 0.320 (0.176) for CC and 0.673 (0.322) for SSAs; CC users had a mean (SD) of 33.3 (23.8) office visits and 0.79 (1.39) hospitalizations; SSA users had 23.1 (12.4) visits and 0.48 (1.07) hospitalizations. Mean total (SD) annual cost for CC users was $124,383 (135,836) and $98,713 (81,495) for SSA users. Among 163 patients with 2 years of follow-up, the annual mean cost in the second-year was $43,026 lower and $8110 higher than the first-year for CC and SSAs, respectively. Conclusions: The majority of patients with lung NETs initiated CC; only about one quarter initiated SSA in the first-line. This descriptive study updates the utilization and costs of pharmacologically-treated lung NETs.
AB - Objective: To assess first-line treatment adherence, healthcare resource utilization, and costs in lung NET patients initiating pharmacologic treatments. Methods: In two US claims databases, patients aged ≥18 years with ≥1 inpatient or ≥2 outpatient lung NET claims within 12 months were identified. The first claim for pharmacologic treatments (e.g. somatostatin analogs [SSAs], cytotoxic chemotherapy [CC], targeted therapy [TT]) following diagnosis, between July 1, 2009–December 31, 2014, was defined as the index date. A 6-month pre-index period without any NET treatment, and ≥1-year post-index enrollment were required. Proportion of days covered (PDC) was calculated during follow-up. Descriptive statistics, including means, standard deviations, and frequencies/percentages for continuous and categorical data, respectively, were reported. Results: Of 354 patients with 1-year of follow-up, 252 initiated CC, 89 SSA, 3 TT, and 10 various combinations. Due to sample sizes, the remaining results focus only on CC and SSAs. Mean PDC (SD) was 0.320 (0.176) for CC and 0.673 (0.322) for SSAs; CC users had a mean (SD) of 33.3 (23.8) office visits and 0.79 (1.39) hospitalizations; SSA users had 23.1 (12.4) visits and 0.48 (1.07) hospitalizations. Mean total (SD) annual cost for CC users was $124,383 (135,836) and $98,713 (81,495) for SSA users. Among 163 patients with 2 years of follow-up, the annual mean cost in the second-year was $43,026 lower and $8110 higher than the first-year for CC and SSAs, respectively. Conclusions: The majority of patients with lung NETs initiated CC; only about one quarter initiated SSA in the first-line. This descriptive study updates the utilization and costs of pharmacologically-treated lung NETs.
KW - Costs
KW - Insurance claims
KW - Lung neuroendocrine tumors
KW - Resource utilization
KW - Treatment adherence
UR - http://www.scopus.com/inward/record.url?scp=85056339844&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056339844&partnerID=8YFLogxK
U2 - 10.1080/03007995.2018.1505277
DO - 10.1080/03007995.2018.1505277
M3 - Article
C2 - 30047289
AN - SCOPUS:85056339844
VL - 34
SP - 2151
EP - 2156
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
SN - 0300-7995
IS - 12
ER -